Fennec (FENC) CCO Terry L. Evans Receives 168-Share Award

What Happened
Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals (FENC), acquired 168 shares on 2026-09-30 through the release of previously restricted stock. The Form 4 reports the shares were acquired at $0.00 per share (no cash paid), reflecting a vesting/release event rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-30; reported on Form 4 filed 2026-10-01 (timely filing).
• Transaction type: Award/release of restricted shares (code A on the Form 4).
• Shares acquired: 168 shares at $0.00 per share (total reported acquisition value $0).
• Footnote: F1 — "Represents shares released from restriction from shares awarded 3/28/2025."
• Shares owned after transaction: Not specified in the provided filing.

Context
This was a release/vesting of prior equity compensation, a common non-market event tied to employee awards. Such releases reflect compensation realization and are not the same signal as an insider purchase (which can be seen as a stronger bullish indicator) or a sale.